Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease, especially in young children. Despite its global impact on healthcare, related to its high prevalence and its association with significant morbidity, the current therapy is still mostly supportive. Moreover, while more than 50 years have passed since the first trial of an RSV vaccine (which unfortunately caused enhanced RSV disease), no vaccine has been approved for RSV prevention. In the last two decades, our understanding of the pathogenesis and immunopathology of RSV have continued to evolve, leading to significant advancements in RSV prevention strategies. These include both the development of new potential vaccines and the successful implementation of passive immunization, which, together, will provide coverage from infancy to old age. In this review, we provide an update of the current treatment options for acute disease (RSV-specific and -non-specific) and different therapeutic approaches focusing on RSV prevention.

MeSH

Respiratory Syncytial Viruses, Vaccines, Viruses, Antibodies, Monoclonal, Therapeutics, Bronchiolitis, Antiviral Agents

Cited by

• Nasal-spraying Bacillus spore probiotics for pneumonia in children with respiratory syncytial virus and bacterial co-infections: a randomized clinical trial. Commun Med (Lond), 2025
• RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial. BMC Infect Dis, 2024
• Prevalence of respiratory viruses in children in Northeast Brazil: The scenario before the COVID-19 pandemic. IJID Reg, 2025
• Kaempferol: A Review of Current Evidence of Its Antiviral Potential. Int J Mol Sci, 2023
• Respiratory syncytial virus: A new era. Rev Esp Quimioter, 2024
• Editorial: Immune response to respiratory viruses and respiratory viral infections in susceptible populations. Front Med (Lausanne), 2023
• Respiratory syncytial virus glycoprotein G impedes CXCR1-activation by CXCL1 and monocyte function. Npj Viruses, 2025
• Retrospective analysis of clinical characteristics and treatment differences between severe and non-severe neonatal types of pneumonia with RSV infection. Medicine (Baltimore), 2025
• Safety, Tolerability, and Pharmacokinetics of Nebulized GB05-Human IFNα1b Inhalation Solution: A Randomized, Placebo-Controlled, Dose-Escalation Phase I Study in Healthy Chinese Adult Volunteers. Infect Dis Ther, 2024
• Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants. Hum Vaccin Immunother, 2025
• The Changing Landscape of Respiratory Syncytial Virus Infections. Pathogens, 2023
• EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults. Clin Transl Sci, 2025
• Respiratory Syncytial Virus Infection: Treatments and Clinical Management. Vaccines (Basel), 2023
• Exploring Therapeutic Targets From Spreading Patterns Against Respiratory Syncytial Virus. FASEB J, 2025
• The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China. Infect Dis Rep, 2024
• Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol. PLoS One, 2025
• Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles. Viruses, 2025
• RSV: an overview of infection in adults. Pneumonia (Nathan), 2025
• Circulation and Seasonality of Respiratory Viruses in Hospitalized Patients during Five Consecutive Years (2019-2023) in Perugia, Italy. Viruses, 2024
• Two centuries of vaccination: historical and conceptual approach and future perspectives. Front Public Health, 2024